← Analyst Upside
AU · rank #7 · 2026-06-05
CORT
NASDAQ · $8.04B
verdict · PROCEED
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.727 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.89 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.186 |
| Analyst upside Consensus target $88.00 | +17.5% |
| Momentum acceleration 3-month minus 12-month momentum. | +118.98% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +98.3% |
| 52w high | $91.00 |
| Market cap | $8.04B |
The AI research card
Independent qualitative review of each pick before the order is placed.
Summary
Corcept is a specialized endocrine/oncology biotech with commercial revenue from Korlym and newly approved Recorlev for Cushing's syndrome, plus late-stage relacorilant in Phase 3 trials.
Rationale
Strong 17.5% analyst upside paired with 4.5/5 rating, positive EPS revisions (+$0.89 in 30d), and 119% momentum acceleration reflect confidence in Q1 beat, raised FY26 guidance ($670–720M), and relacorilant approval trajectory.
Material risks
- 1Regulatory concentration—relacorilant approval and label expansion for Korlym/Recorlev are binary events; any FDA delay, safety signal, or restrictive labeling could trigger sharp downside.
- 2Portfolio narrowness—Cushing's syndrome and related indications dominate revenue; oncology upside is unproven and faces entrenched competition; loss of Korlym exclusivity or reimbursement pressure poses structural risk.
Verdict reasoning
two_stage score=+3/3 verdicts={'gemini': 'PROCEED', 'openai': 'PROCEED', 'claude': 'PROCEED'} brief=caller-supplied